· For research use only. Not for human consumption.
For research use only. Not for human consumption.
What is Melanotan II? It’s a name that shows up frequently in research peptide catalogs, and it has a genuinely interesting scientific backstory. Melanotan II is a synthetic peptide — a laboratory-made chain of amino acids — that was developed at the University of Arizona in the late 1980s and early 1990s.
What makes it unusual? It’s a cyclic peptide, meaning its chain forms a ring rather than staying straight. Think of the difference between a necklace (straight chain) and a bracelet (ring). That ring structure affects how Melanotan II behaves in biological systems and is part of what drew researchers’ attention in the first place. This is particularly relevant for what is melanotan ii research.
This guide covers the basics: what Melanotan II is, where it came from, what makes its structure interesting, and what the melanocortin receptor system is all about. Plain English throughout. No medical claims. Just science, explained simply.
TL;DR: Melanotan II is a synthetic cyclic peptide analog of alpha-MSH, developed at the University of Arizona. Hadley and Dorr (2006) reviewed its research history in the Annals of the New York Academy of Sciences (PMID: 16426078). It interacts with melanocortin receptors. Melanotan II is sold exclusively for laboratory research. Not for human consumption.
What Is Melanotan II? Understanding the Basics
Melanotan II is a synthetic analog of alpha-MSH (alpha-melanocyte-stimulating hormone). Hadley and Dorr (2006) published a comprehensive review of Melanotan II’s research history, documenting its development and biological profile over two decades of investigation (PMID: 16426078). The peptide interacts with the melanocortin receptor system.
Let’s start with alpha-MSH. It’s a 13-amino-acid hormone your body produces naturally. Alpha-MSH is involved in melanin production — melanin is the pigment that gives skin, hair, and eyes their color. When alpha-MSH binds to specific receptors on skin cells, those cells produce more melanin.
Researchers at the University of Arizona wanted to study alpha-MSH’s biology more closely. But alpha-MSH, like many natural hormones, breaks down quickly in the body. So they built a shorter, more stable version. That’s Melanotan II — a modified, truncated version of alpha-MSH designed to be more resistant to enzymatic breakdown.
The “II” in the name distinguishes it from Melanotan I, an earlier analog. Melanotan I is a linear peptide (straight chain). Melanotan II is cyclic (ring-shaped). That structural difference significantly affects how each version interacts with receptors.
Melanotan II is a synthetic cyclic peptide developed at the University of Arizona as an analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Hadley and Dorr (2006) reviewed two decades of Melanotan research in the Annals of the New York Academy of Sciences, documenting its development, structure, and biological interactions with melanocortin receptors (PMID: 16426078).
What Makes Melanotan II a Cyclic Peptide?
Most peptides are linear — their amino acids form a straight chain, like beads on a string. Melanotan II is different. Its chain loops back on itself and forms a ring. That ring structure is what scientists mean when they say “cyclic.”
Why does the ring matter? Two big reasons. First, cyclic peptides are generally more resistant to enzymatic degradation. Enzymes that break down peptides usually attack the ends of the chain. A ring has no ends. It’s like trying to unravel a bracelet versus unraveling a necklace — the bracelet is harder to pull apart. This is particularly relevant for what is melanotan ii research.
Second, the ring shape changes how the peptide fits into receptors. Receptors are molecular locks, and the peptide’s 3D shape determines which locks it can open. A ring-shaped peptide presents a different surface to receptors than a linear one. Dorr et al. (1996) examined Melanotan II’s receptor interactions and documented its biological activity profile in preclinical models (PMID: 8839487).
Think of it like the difference between a flat key and a tubular key. Both open locks, but they fit into completely different types of locks. Melanotan II’s cyclic structure gives it access to receptor interactions that a linear version of the same amino acids wouldn’t have.
[ORIGINAL DATA] The decision to make Melanotan II cyclic rather than linear was a deliberate engineering choice by the University of Arizona team. It represented an early example of peptide cyclization being used to improve both stability and receptor selectivity — a technique that’s now standard in peptide chemistry.
What Is the Melanocortin Receptor System?
To understand what Melanotan II does in research, you need to understand the melanocortin receptor system. This is a family of five receptor subtypes, labeled MC1R through MC5R. Each receptor sits on the surface of different cell types throughout the body.
Receptors are like locks on the doors of cells. When the right molecule (the key) fits in, it triggers a response inside the cell. Different melanocortin receptors trigger different responses:
- MC1R: Found primarily on melanocyte cells (the cells that produce melanin pigment)
- MC2R: The primary receptor for full-length ACTH and cortisol production
- MC3R and MC4R: Found in the brain, involved in various signaling pathways
- MC5R: Found in several tissues, with roles still being investigated
Melanotan II interacts with multiple melanocortin receptor subtypes. That’s called “non-selective” binding — it fits into several different locks rather than just one. Hadley and Dorr (2006) noted this broad receptor profile as a key feature of Melanotan II’s biological activity (PMID: 16426078).
This non-selectivity is important for understanding Melanotan II’s research profile. A peptide that binds to multiple receptors can trigger multiple biological responses simultaneously. For researchers, that means Melanotan II isn’t a precision tool for studying one receptor — it’s more useful for understanding the melanocortin system as a whole.
How Was Melanotan II Developed?
The development story began at the University of Arizona in the late 1980s. Researchers led by Mac Hadley and colleagues were studying the melanocortin system and wanted better tools for preclinical investigation. Natural alpha-MSH was too unstable for many experimental designs.
Dorr et al. (1996) documented the compound’s biological activity in preclinical models, contributing to the foundation of Melanotan II research (PMID: 8839487). The team systematically modified alpha-MSH’s amino acid sequence, shortening it and introducing the cyclic structure to improve stability.
The result was a seven-amino-acid cyclic peptide that maintained biological activity at melanocortin receptors but lasted much longer than natural alpha-MSH in experimental settings. That stability made it a practical research tool for studying melanocortin biology in a way that the natural hormone couldn’t support.
This development approach — taking a natural hormone, trimming it down, and modifying it for stability — is common in peptide research. Semax followed a similar path with ACTH. Selank did the same with tuftsin. The goal is always the same: create a stable, usable research compound from a fragile natural template.
[UNIQUE INSIGHT] Melanotan II’s development at the University of Arizona gives it a well-documented Western academic provenance — unusual among peptides often discussed alongside Russian-developed compounds like Selank and Semax. Its research lineage through American university publications makes it one of the most thoroughly documented research peptides in the melanocortin field.
What Should Researchers Know About Sourcing Melanotan II?
Same quality rules apply here as with any research peptide. HPLC purity above 98% is the standard threshold. Mass spectrometry should confirm the cyclic structure and correct molecular weight. Batch-specific COAs from an independent third-party lab are non-negotiable for serious research applications.
For cyclic peptides specifically, mass spectrometry verification is especially important. Cyclization doesn’t always proceed perfectly during synthesis. An improperly cyclized peptide would have a linear structure and different receptor interactions — functionally, it would be a different compound. MS confirmation rules out this possibility.
Alpha Peptides carries research-grade Melanotan II with batch-specific COA documentation, including HPLC purity data and mass spectrometry confirmation. Full records are available at alpha-peptides.com/coas/.
Frequently Asked Questions About Melanotan II
Is Melanotan II natural?
No. Melanotan II is a synthetic peptide designed in a laboratory. It’s based on alpha-MSH, which is a natural hormone, but Melanotan II itself is a modified, shortened, and cyclized version that doesn’t occur in nature. It was specifically engineered for research purposes at the University of Arizona.
What’s the difference between Melanotan I and Melanotan II?
Melanotan I is a linear (straight-chain) analog of alpha-MSH. Melanotan II is a cyclic (ring-shaped) analog. The structural difference affects receptor selectivity and stability. Melanotan II interacts with a broader range of melanocortin receptor subtypes compared to Melanotan I, as documented by Hadley and Dorr (2006) (PMID: 16426078).
What are melanocortin receptors?
Melanocortin receptors are a family of five receptor subtypes (MC1R through MC5R) found on cell surfaces throughout the body. They respond to melanocortin peptides like alpha-MSH and ACTH. Different subtypes are located on different cell types and trigger different cellular responses when activated. Melanotan II interacts with multiple subtypes in this family.
For research use only. Not for human consumption. Melanotan II is an experimental research peptide with no FDA-approved therapeutic applications. All information on this page is provided for educational purposes relating to laboratory and preclinical research.
